CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,087 enrolled
Drug / intervention
PrEPdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05746065
NCT05746065N/ACompleted
CompareCT.gov

A Cohort for Evaluation of Open-label PrEP Delivery and PrEP Preferences Among African Women

University of Washington·observational·Posted Feb 27, 2023·Updated May 8, 2024

In Brief

An observational study evaluating PrEP for HIV Infections. Completed, enrolled 3,087 participants across 20 sites in 7 countries.

Detailed Summary

INSIGHT is a Prospective, Observational, open-label cohort study on women in Sub-Saharan Africa on PrEP screening, informed choice, and compliance. There are no specific intervention arms or comparative treatment plans. We will follow and observe participants taking PrEP, not taking PrEP, as well as those who begin or end PrEP during the course of the observational period.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesEswatini, Kenya, Malawi, South Africa, Uganda, Zambia, Zimbabwe
CollaboratorsBill and Melinda Gates Foundation

Timeline

N/ACompletedFinished
2023202420252026
First PostedFeb 27, 2023
Enrollment StartAug 1, 2022
Primary CompletionAug 1, 2023
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 3.3 years ago

Interventions

PrEPdrug

Eligible women will be prescribed PrEP intake in accordance to standard of care should they choose. We are interested in observing adherence, barriers to adherence, and other factors that effect sexual health.